Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Fundamental Analysis

NASDAQ:CDTX - Nasdaq - US1717572069 - Common Stock - Currency: USD

18.63  -0.52 (-2.72%)

Fundamental Rating

2

Taking everything into account, CDTX scores 2 out of 10 in our fundamental rating. CDTX was compared to 563 industry peers in the Biotechnology industry. The financial health of CDTX is average, but there are quite some concerns on its profitability. CDTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CDTX has reported negative net income.
CDTX had a negative operating cash flow in the past year.
In the past 5 years CDTX always reported negative net income.
CDTX had a negative operating cash flow in each of the past 5 years.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of CDTX (-79.06%) is worse than 68.97% of its industry peers.
CDTX has a Return On Equity (-103.99%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.06%
ROE -103.99%
ROIC N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CDTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDTX has been increased compared to 1 year ago.
Compared to 5 years ago, CDTX has more shares outstanding
CDTX has a better debt/assets ratio than last year.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -1.75, we must say that CDTX is in the distress zone and has some risk of bankruptcy.
CDTX's Altman-Z score of -1.75 is in line compared to the rest of the industry. CDTX outperforms 56.56% of its industry peers.
CDTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CDTX has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.75
ROIC/WACCN/A
WACC10.09%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.25 indicates that CDTX has no problem at all paying its short term obligations.
CDTX has a Current ratio (4.25) which is comparable to the rest of the industry.
A Quick Ratio of 4.25 indicates that CDTX has no problem at all paying its short term obligations.
With a Quick ratio value of 4.25, CDTX perfoms like the industry average, outperforming 51.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.25
Quick Ratio 4.25
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CDTX have decreased strongly by -41.54% in the last year.
The Revenue for CDTX has decreased by -98.00% in the past year. This is quite bad
The Revenue for CDTX have been decreasing by -42.85% on average. This is quite bad
EPS 1Y (TTM)-41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.19%
Revenue 1Y (TTM)-98%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%

3.2 Future

CDTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.02% yearly.
CDTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 77.85% yearly.
EPS Next Y9.53%
EPS Next 2Y4.46%
EPS Next 3Y4.56%
EPS Next 5Y14.02%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-1.93%
Revenue Next 5Y77.85%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 200M 400M 600M
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.46%
EPS Next 3Y4.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (5/9/2025, 8:00:02 PM)

18.63

-0.52 (-2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11
Inst Owners70.5%
Inst Owner Change-5.07%
Ins Owners0.71%
Ins Owner Change0.94%
Market Cap233.81M
Analysts84.62
Price Target38.76 (108.05%)
Short Float %4.45%
Short Ratio3.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.98%
Min EPS beat(2)-45.43%
Max EPS beat(2)43.48%
EPS beat(4)2
Avg EPS beat(4)-240.46%
Min EPS beat(4)-1017.65%
Max EPS beat(4)57.74%
EPS beat(8)5
Avg EPS beat(8)-84.93%
EPS beat(12)7
Avg EPS beat(12)-54.55%
EPS beat(16)9
Avg EPS beat(16)-23.15%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-65.5%
Min Revenue beat(4)-100%
Max Revenue beat(4)31.7%
Revenue beat(8)4
Avg Revenue beat(8)-19.8%
Revenue beat(12)6
Avg Revenue beat(12)-11.49%
Revenue beat(16)9
Avg Revenue beat(16)3.86%
PT rev (1m)0%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.69%
EPS NY rev (1m)10.63%
EPS NY rev (3m)-6.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.68
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-10.87
EYN/A
EPS(NY)-10.44
Fwd EYN/A
FCF(TTM)-14.08
FCFYN/A
OCF(TTM)-14.07
OCFYN/A
SpS0.7
BVpS13.01
TBVpS13.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.06%
ROE -103.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.36%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.25
Quick Ratio 4.25
Altman-Z -1.75
F-Score2
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)188.62%
Cap/Depr(5y)130.51%
Cap/Sales(3y)3.7%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.19%
EPS Next Y9.53%
EPS Next 2Y4.46%
EPS Next 3Y4.56%
EPS Next 5Y14.02%
Revenue 1Y (TTM)-98%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-1.93%
Revenue Next 5Y77.85%
EBIT growth 1Y-278.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-670.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-686.97%
OCF growth 3YN/A
OCF growth 5YN/A